TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TG Therapeutics, Inc.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Hercules Capital

#Milestones – TG Therapeutics announced preliminary 4th quarter and full year 2023 net BRIUMVI revenue (unaudited), as well as our anticipated development milestones for 2024! Read the press release here: bit.ly/4aNu3nd #FearlessForPatients #TGTX #Strategy2024

#DontMissIt – TG CEO Mike Weiss will be presenting at the 42nd Annual J.P.Morgan Healthcare Conference in 15 minutes! Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#DontMissIt – TG CEO Mike Weiss will be presenting today at the 42nd Annual J.P.Morgan Healthcare Conference - Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Live Webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

#Breaking - Just announced a Global License Agreement with Precision BioSciences for the Development & Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases. Details: bit.ly/3vzHEhG #FearlessForPatients #TGTX

#SaveTheDate - TG CEO Mike Weiss will present at the 42nd Annual J.P.Morgan Healthcare Conference next week. Live webcast Tues, Jan. 9th @ 4:30PM PT/7:30PM ET. Details: bit.ly/47qzxS7 webcast at: https://lnkd.in/eguXMYM #JPM24 #FearlessForPatients #TGTX

The team at TG Therapeutics wishes you and your family a very happy and healthy holiday season! #TGTX #FearlessForPatients

#Today - Join the Fireside Chat with TG's CEO Mike Weiss during the 6th Annual Evercore ISI HealthCONx Conference at 2:10PM ET today. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#SaveTheDate Join our CEO Mike Weiss for a Fireside Chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th at 2:10PM ET. Webcast at: https://lnkd.in/eguXMYM #TGTX #EvercoreISI #FearlessForPatients

#Reminder – Don’t miss today’s Fireside chat with TG’s CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast today, Nov. 6th at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

#DontMissIt – Join the Fireside Chat with TG CEO Mike Weiss at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference. Webcast on Mon., Nov. 6 at 3:10PM ET at https://lnkd.in/eC6nRGS #TGTX #GuggenheimSecurities #FearlessForPatients

COM:TGTHERAPEUTICS

TG Therapeutics Inc

Last Close

34.55

22/11 21:00

Market Cap

3.17B

Beta: -

Volume Today

2.57M

Avg: -

People Not Available